Related Experiment Video

Updated: Jun 23, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.3K

Continued Success of Venetoclax in t(11;14) Multiple Myeloma Despite Negative Trials

Zachary M Avigan, Joshua Richter Md

    Oncology (Williston Park, N.Y.)
    |June 20, 2024
    PubMed

    Abstract:

    The June Hot Topics focuses on the challenges venetoclax regimens have faced in multiple myeloma trials.

    More Related Videos

    Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
    07:39

    Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

    Published on: June 6, 2025

    73
    Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
    06:15

    Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

    Published on: October 27, 2014

    27.4K

    Related Experiment Videos

    Last Updated: Jun 23, 2025

    Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
    09:34

    Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

    Published on: February 17, 2022

    3.3K
    Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
    07:39

    Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

    Published on: June 6, 2025

    73
    Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
    06:15

    Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

    Published on: October 27, 2014

    27.4K

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    7.5K
    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    7.5K
    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    4.9K
    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
    4.9K

    Articles linked to this work by shared authors, journal, and citation graph.

    Persistence of mucosal CAR-T cells and inflammatory remodeling in enterocolitis associated with BCMA CAR-T cell therapy.

    Nature medicine·2026

    Belantamab mafodotin, a BCMA-directed antibody-drug conjugate for multiple myeloma.

    Future oncology (London, England)·2026

    Genomic features of clonal hematopoiesis-associated genes in primary and CAR T-cell-related secondary T-cell malignancies.

    Blood neoplasia·2026

    Linvoseltamab, a BCMA-directed CD3 T-cell engager for multiple myeloma: a patient-centric option via a response-adapted dosing regimen.

    Expert review of hematology·2026

    Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy.

    Clinical cancer research : an official journal of the American Association for Cancer Research·2025

    A novel application of XPO1 inhibition for the treatment of myelofibrosis.

    Blood neoplasia·2025

    Advancing Multidisciplinary Care and Health Equity in Metastatic Breast Cancer.

    Oncology (Williston Park, N.Y.)·2026

    Homologous Recombination and Mismatch Repair Assessment in Men With Advanced Prostate Cancer: A Cross-Sectional Study From a Center in Mexico City.

    Oncology (Williston Park, N.Y.)·2026

    Access to Care and Drug Prices: Recent Department of Health and Human Services Guidance.

    Oncology (Williston Park, N.Y.)·2026

    Clinical Outcomes of Acute Pancreatitis in Patients With Multiple Myeloma.

    Oncology (Williston Park, N.Y.)·2026

    Primary Malignant Melanoma of the Colon: A Rare and Challenging Diagnosis.

    Oncology (Williston Park, N.Y.)·2026

    Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma.

    Oncology (Williston Park, N.Y.)·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us